Ovid Therapeutics

OVID

Market cap $89.6M

Overview Fund Activity

1.26 USD

+0.01

0.8%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.28

+0.02

1.59%

1 day

0.8%

5 days

4.13%

1 month

130.35%

3 months

335.53%

6 months

152%

Year to date

31.52%

1 year

13.51%

5 years

-79.81%

10 years

-89.71%

About: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Employees: 23

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

15% less funds holding

Funds holding: 82 [Q1] → 70 (-12) [Q2]

14.7% less ownership

Funds ownership: 65.28% [Q1] → 50.58% (-14.7%) [Q2]

18% less capital invested

Capital invested by funds: $14.5M [Q1] → $11.9M (-$2.61M) [Q2]

27% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 22

39% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 28

See Fund Rankings

Financial journalist opinion

Zacks Investment Research

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to earnings of $0.12 per share a year ago.

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 $7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone royalties, delivering capital to the Company from a non-pipeline asset OV4071, the first ever oral KCC2 direct activator, is completing an IND-enabling package; Ovid anticipates first-in-human studies in Q2 2026 Cash, cash equivalents and marketable securities of $38.3 million as of June 30, 2025 are expected to support currently planned operations and development programs into early 2H 2026 NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the second quarter ended June 30, 2025. “Our pipeline continues to advance across multiple fronts, with several key readouts anticipated in the near and mid-term.

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, announced today that the Company's management will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need.

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costs Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costs

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Zacks Investment Research

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid's first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-end Cash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the first quarter ended March 31, 2025. “We're off to a strong start across our pipeline and programs in what will be a defining year for Ovid,” said Dr. Jeremy Levin, D.Phil.

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Zacks Investment Research

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks Investment Research

Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.22 per share a year ago.

Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinic Topline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerability OV350, Ovid's first program in its KCC2 direct activator library, initiated a first-in-human study in Q1 2025 Cash, cash equivalents and marketable securities of $53.1 million as of December 31, 2024, are expected to support operations and development programs into the second half of 2026 NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024.

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors.

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

See News Rankings

Charts implemented using Lightweight Charts™